Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 23Unknown 4Terminated 4Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Hepatocellular 6Leukemia, Myeloid, Acute 3Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Locally Advanced Thyroid Gland Carcinoma 1Liver Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1HCC 1Fibrolamellar hepatocellular carcinoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 49Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 16Cyclophosphamide 14Cisplatin 14Paclitaxel 13Carboplatin 13Bevacizumab 13Leucovorin 11Irinotecan 11Fluorouracil 11Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Capecitabine 10trastuzumab deruxtecan 9fludarabine 9cemiplimab 8Doxorubicin 8Cetuximab 8abemaciclib 7Trastuzumab 7Pemetrexed 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × Sorafenib × Clear all
NCT02029001 2025-08-07

MOST plus

Centre Leon Berard

Phase 2 Recruiting
900 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡